No annual revenue total was found in DRUGS MADE IN AMERICA ACQUISITION II CORP.'s SEC filings.
Drugs Made In America Acquisition II Corp. (DMII) files with the SEC under industry code 6770, Blank Checks. As of Jun 30, 2026 it held $174,974 in cash and investments and $450,000 in total debt.
Revenue
—
Net income
$4.19M
Operating cash flow
$-1.02M
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
63.70M
Net cash
$-275,026
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Blank Checks (SIC 6770)
- Listed as
- DMII (Nasdaq), DMIIR (Nasdaq), DMIIU (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 2040475
Other Blank Checks companies
- EQV Ventures Acquisition Corp. II EVAC
- Bain Capital GSS Investment Corp. BCSS
- Cantor Equity Partners IV, Inc. CEPF
- Churchill Capital Corp XII CXII
- American Exceptionalism Acquisition Corp. A AEXA
- New America Acquisition I Corp. NWAX
- Ares Acquisition Corp III AAC
- Mountain Lake Acquisition Corp. II MLAA
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
|---|---|
| Operating income | -$488,385 |
| Net income | $4.2M |
| Operating cash flow | -$1.0M |
| Total assets | $505.0M |
| Total liabilities | $17.8M |
| Stockholders' equity | -$17.8M |
| Cash and investments | $223 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Material agreement
|
Apr 28, 2026 | Apr 22, 2026 |
| 10-K | Annual report | Apr 15, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Material agreement, New debt
|
Apr 3, 2026 | Mar 24, 2026 |
| 8-K |
Current report
Material agreement, New debt, Other events
|
Mar 17, 2026 | Mar 11, 2026 |
All 45 Drugs Made In America Acquisition II Corp. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.